T Teva Pharmaceutil Industries Ltd ADR
| Market Cap | $35.03B |
| P/E Ratio | 24.86 |
| Forward P/E | 9.74 |
| Dividend Yield | — |
| Beta | 0.76 |
| 52W Range | $12.82 - $36.25 |
| # Hedge Funds | 7 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 4 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Harry Burn Sound Shore Management | 4.28% | $134.51M | 4,309,906 | Reduce 23.68% |
| David Einhorn DME Capital Management | 3.35% | $95.46M | 3,058,734 | Buy |
| Lee Ainslie Maverick Capital | 0.00% | $0 | 0 | Sold |
| Viking Global Investors Viking Global Investors | 0.00% | $0 | 0 | Sold |
Insider Trading
| Insider Name of the company insider who made the trade 46 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Sabag MarkSee "Remarks" | Sale | 62,102 | $30.14 | $1.87M | 17 Mar 2026 | 17 Mar 2026 |
| Francis Richard DPresident and CEO | Sale | 20,025 | $31.67 | $634.16K | 05 Mar 2026 | 05 Mar 2026 |
| Shields MatthewEVP, Global Operations | Sale | 17,295 | $31.67 | $547.70K | 05 Mar 2026 | 05 Mar 2026 |
| Hughes Eric ASee "Remarks" | Sale | 9,533 | $31.67 | $301.89K | 05 Mar 2026 | 05 Mar 2026 |
| Jover PlacidSee "Remarks" | Sale | 14,150 | $31.67 | $448.11K | 05 Mar 2026 | 05 Mar 2026 |
| Savage BrianInterim Chief Legal Officer | Sale | 1,127 | $31.67 | $35.69K | 05 Mar 2026 | 05 Mar 2026 |
| Daniell RichardEVP, Europe Commercial | Sale | 17,295 | $31.67 | $547.70K | 05 Mar 2026 | 05 Mar 2026 |
| Fox ChristineEVP, U.S. Commercial | Sale | 7,924 | $31.67 | $250.94K | 05 Mar 2026 | 05 Mar 2026 |
| Daniell RichardEVP, Europe Commercial | Sale | 37,372 | $32.95 | $1.23M | 04 Mar 2026 | 06 Mar 2026 |
| Francis Richard DPresident and CEO | Sale | 23,393 | $32.46 | $759.44K | 04 Mar 2026 | 06 Mar 2026 |
| Hughes Eric ASee "Remarks" | Sale | 11,277 | $32.46 | $366.10K | 04 Mar 2026 | 06 Mar 2026 |
| Fox ChristineEVP, U.S. Commercial | Sale | 9,098 | $32.46 | $295.36K | 04 Mar 2026 | 06 Mar 2026 |
| Savage BrianInterim Chief Legal Officer | Sale | 1,186 | $32.46 | $38.50K | 04 Mar 2026 | 06 Mar 2026 |
| Savage BrianInterim Chief Legal Officer | Sale | 1,489 | $32.46 | $48.34K | 04 Mar 2026 | 06 Mar 2026 |
| Daniell RichardEVP, Europe Commercial | Sale | 20,461 | $32.46 | $664.26K | 04 Mar 2026 | 06 Mar 2026 |
| Daniell RichardEVP, Europe Commercial | Sale | 33,512 | $32.46 | $1.09M | 04 Mar 2026 | 06 Mar 2026 |
| Eric A HughesSee "Remarks" | Sale | 11,277 | $32.46 | $366.10K | 04 Mar 2026 | 06 Mar 2026 |
| Brian SavageInterim Chief Legal Officer | Sale | 1,489 | $32.46 | $48.34K | 04 Mar 2026 | 06 Mar 2026 |
| Brian SavageInterim Chief Legal Officer | Sale | 1,186 | $32.46 | $38.50K | 04 Mar 2026 | 06 Mar 2026 |
| Richard DaniellEVP, Europe Commercial | Sale | 37,372 | $32.95 | $1.23M | 04 Mar 2026 | 06 Mar 2026 |
| Richard DaniellEVP, Europe Commercial | Sale | 20,461 | $32.46 | $664.26K | 04 Mar 2026 | 06 Mar 2026 |
| Christine FoxEVP, U.S. Commercial | Sale | 9,098 | $32.46 | $295.36K | 04 Mar 2026 | 06 Mar 2026 |
| Richard D FrancisPresident and CEO | Sale | 23,393 | $32.46 | $759.44K | 04 Mar 2026 | 06 Mar 2026 |
| Richard DaniellEVP, Europe Commercial | Sale | 33,512 | $32.46 | $1.09M | 04 Mar 2026 | 06 Mar 2026 |
| Daniell RichardEVP, Europe Commercial | Sale | 66,735 | $32.36 | $2.16M | 03 Mar 2026 | 05 Mar 2026 |
| Daniell RichardEVP, Europe Commercial | Sale | 62,250 | $32.36 | $2.01M | 03 Mar 2026 | 05 Mar 2026 |
| Savage BrianInterim Chief Legal Officer | Sale | 1,274 | $32.36 | $41.23K | 03 Mar 2026 | 05 Mar 2026 |
| Francis Richard DPresident and CEO | Sale | 412,032 | $32.36 | $13.33M | 03 Mar 2026 | 05 Mar 2026 |
| Francis Richard DPresident and CEO | Sale | 30,903 | $32.36 | $1.00M | 03 Mar 2026 | 05 Mar 2026 |
| Hughes Eric ASee "Remarks" | Sale | 68,685 | $32.36 | $2.22M | 03 Mar 2026 | 05 Mar 2026 |
| Hughes Eric ASee "Remarks" | Sale | 12,077 | $32.36 | $390.81K | 03 Mar 2026 | 05 Mar 2026 |
| Kalif Eliyahu SharonEVP, Chief Financial Officer | Sale | 345,810 | $33.64 | $11.63M | 26 Feb 2026 | 02 Mar 2026 |
| Francis Richard DPresident and CEO | Sale | 161,656 | $34.22 | $5.53M | 15 Feb 2026 | 18 Feb 2026 |
| Francis Richard DPresident and CEO | Sale | 286,122 | $34.22 | $9.79M | 15 Feb 2026 | 18 Feb 2026 |
| MIGNONE ROBERTO | Sale | 77,400 | $30.24 | $2.34M | 16 Dec 2025 | 18 Dec 2025 |
| Weiss AmirChief Accounting Officer | Sale | 12,300 | $30.20 | $371.50K | 16 Dec 2025 | 18 Dec 2025 |
| Daniell RichardExec. VP, European Commercial | Sale | 115,468 | $28.68 | $3.31M | 09 Dec 2025 | 11 Dec 2025 |
| Sabag MarkSee "Remarks" | Sale | 98,168 | $28.70 | $2.82M | 09 Dec 2025 | 11 Dec 2025 |
| Sabag MarkSee "Remarks" | Sale | 118,724 | $28.75 | $3.41M | 09 Dec 2025 | 11 Dec 2025 |
| MIGNONE ROBERTO | Sale | 50,000 | $26.03 | $1.30M | 26 Nov 2025 | 01 Dec 2025 |
| Roberto MignoneDirector | Sale | 50,000 | $26.03 | $1.30M | 26 Nov 2025 | 01 Dec 2025 |
| Fox ChristineEVP, Head of U.S. Commercial | Sale | 28,229 | $24.78 | $699.52K | 20 Nov 2025 | 24 Nov 2025 |
| Christine FoxEVP, Head of U.S. Commercial | Sale | 28,229 | $24.78 | $699.52K | 20 Nov 2025 | 24 Nov 2025 |
| Fox ChristineEVP, Head of U.S. Commercial | Sale | 30,000 | $25.11 | $753.32K | 14 Nov 2025 | 18 Nov 2025 |
| Weiss AmirChief Accounting Officer | Sale | 12,300 | $24.44 | $300.56K | 06 Nov 2025 | 10 Nov 2025 |
| MIGNONE ROBERTO | Sale | 200,000 | $24.11 | $4.82M | 06 Nov 2025 | 10 Nov 2025 |
Frequently Asked Questions
What is TEVA stock price today?
Teva Pharmaceutil Industries Ltd ADR (TEVA) is currently trading at $30.08. The stock has a 52-week range of $12.82 to $36.25 and a market capitalization of $35.03B.
Is TEVA a good stock to buy in 2026?
Teva Pharmaceutil Industries Ltd ADR has a P/E ratio of 24.9 (forward P/E: 9.7), a dividend yield of none, and 1-year performance of +102.6%. 4 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling TEVA stock?
There have been 46 insider transactions for TEVA in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has TEVA stock performed over the past year?
Teva Pharmaceutil Industries Ltd ADR (TEVA) has returned +102.6% over the past 12 months. The stock traded between $12.82 and $36.25 during this period, and is currently at $30.08.
Which hedge funds own TEVA (Teva Pharmaceutil Industries Ltd ADR)?
4 tracked hedge funds currently hold TEVA in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is TEVA's market cap and valuation?
Teva Pharmaceutil Industries Ltd ADR (TEVA) has a market capitalization of $35.03B. The trailing P/E ratio is 24.9 and forward P/E is 9.7. The stock is classified in the Healthcare sector.
What is TEVA's revenue and profitability?
Teva Pharmaceutil Industries Ltd ADR reported revenue of $17.26B with net income of $1.41B and a profit margin of 0.08%. The stock has a beta of 0.76.
What sector is TEVA in and who are its biggest institutional holders?
Teva Pharmaceutil Industries Ltd ADR (TEVA) operates in the Healthcare sector. It is held by 4 tracked hedge funds. See the ownership table above for the complete list.